After 20 years of preliminary research in the labs of Max Delbrück Center & #CharitéBerlin, a new T-cell immunotherapy against #MultipleMyeloma is now in clinical trials. The innovative treatment is designed to teach the immune system to fight the cancer cells. charite.de/en/service/pre…

Sorry, für heute muss ich erst einmal weg. Ich bin echt enttäuscht und fassungslos zugleich. Mit Beleidigungen kann ich umgehen, aber einige Wortmeldungen sind für mich echt harter Tobak.

After years of hard work (literally) involving blood, sweat and tears, I am thrilled to be able share this! We developed TCRs targeting one of the most common mutations in #lymphoma. Online at Journal for ImmunoTherapy of Cancer : jitc.bmj.com/content/9/7/e0… Max Delbrück Center Charité - Universitätsmedizin Berlin

Important preclinical study to advance tumor-specific adoptive T cell therapy for patients with MYD88 mutant lymphoma. Congratulations to Antonia Busses group jitc.bmj.com/content/9/7/e0…

Richie, Stefan and coworkers reveal a critical role for CXCR4 in aggressive forms of CLL : nature.com/articles/s4137…

Writing in Nature Communications, a team of researchers from #CharitéBerlin and Goethe-Universität untangle a key process involved in #Lymphoma development, which controls DNA damage repair and offers a potential treatment target. charite.de/en/service/pre…

New treatment strategy for #PancreaticCancer: Writing in PNASNews, a team of researchers from #CharitéBerlin describe how a key factor which enables the suppression of cancer cell death (#apoptosis) can be used to block #TumorGrowth. charite.de/en/service/pre…

A team of researchers from #CharitéBerlin reveal in Journal of Clinical Investigation how cancer cells can evade immunosurveillance. A cellular signaling pathway activated as part of this process may offer a new target for more effective cancer immunotherapy treatments. jci.org/articles/view/…

It's not all about #ubiquitin: Listen to Uta Demel from Keller-Lab@Charite Max Delbrück Center how inhibition of SUMOylation leads to increased antigen presentation and T-cell activation

Dr. Uta Demel von #CharitéBerlin und Max Delbrück Center ist für eine ihrer Publikationen mit dem Forschungspreis der Arbeitsgemeinschaft DAG-HSZT ausgezeichnet worden. Herzlichen Glückwunsch! charite.de/forschung/them…

In Annals of Oncology, results from the German 🇩🇪 #PrecisionMedicine 🧬🎯💊 NCT/DKTK MASTER trial inform on the association of cancer perdisposing genes and rare cancer annalsofoncology.org/article/S0923-…

We are looking for a talented PhD student. See our announcement at Charité Homepage and Jobvector!

Great opprtunity for a postdoctoral researcher/team leader at Keller-Lab@Charite karriere.charite.de/stellenangebot… Looking forward to your application!

Check out our recent publication in EMBO Mol Med: Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response embopress.org/doi/full/10.15…

CIAO Wolf Lab for Tumor Biochemistry 🤍 Today we say goodbye to Anneli and Elmar after more than a decade in the institute. Both of you shaped our institute and the science done Universität Würzburg #UniWürzburg! We wish you all the best for your new adventure Universität Kiel CAU 🎓!

Researchers generated a new mouse model of #STAT3GOF syndrome that can recapitulate the IL-6-gp130-STAT3 pathway and multi-organ autoimmunity—addressing the lack of reliable animal models for this rare autoimmune condition. Keller-Lab@Charite Charité - Universitätsmedizin Berlin scim.ag/5Xp

Engineering a mouse model of #autoimmunity, researchers at Charité - Universitätsmedizin Berlin have made strides in understanding the basis of a mysterious and rare autoimmune disorder named STAT3GOF syndrome and identified sex-specific differences in the disorder. Keller-Lab@Charite scim.ag/60n

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus | New England Journal of Medicine nejm.org/doi/full/10.10…

Early View | Haematologica haematologica.org/article/view/h… Finally first results from our Phase 1 TCR study targeting MAGE-A1 in myeloma! Hopefully more to come in advanced solid tumors where need for innovative (cellular) therapies is still HUGE.